Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease.
about
Precipitating factors and targeted therapies in combating the perils of sickle cell disease--- A special nutritional considerationFetal globin gene repressors as drug targets for molecular therapies to treat the β-globinopathiesTrials with 'epigenetic' drugs: an updateSickle cell disease biochip: a functional red blood cell adhesion assay for monitoring sickle cell disease.Epigenetic modifications: basic mechanisms and role in cardiovascular disease.5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signalEpigenetic regulation of HIV-1 latency by cytosine methylationNovel Inducers of Fetal Globin Identified through High Throughput Screening (HTS) Are Active In Vivo in Anemic Baboons and Transgenic MiceRole of protein tyrosine phosphatases in cancerHeterogeneous red blood cell adhesion and deformability in sickle cell disease.Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease.The effect of chemotherapeutic agents on telomere length maintenance in breast cancer cell lines.Identification of novel DNA methylation inhibitors via a two-component reporter gene system.Decitabine suspends human CD34+ cell differentiation and proliferation during lentiviral transduction.Current therapy of myelodysplastic syndromesAcute chest syndrome: sickle cell disease.Genome-wide epigenetic modifications in cancer.Evolution of decitabine development: accomplishments, ongoing investigations, and future strategiesFetal hemoglobin in sickle cell anemiaEvaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes.A pilot study of subcutaneous decitabine in β-thalassemia intermediaPharmacotherapy in sickle cell disease--state of the art and future prospectsFetal hemoglobin reactivation and cell engineering in the treatment of sickle cell anemia.Sickle cell disease: old discoveries, new concepts, and future promise.Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabineDemethylation of DNA by decitabine in cancer chemotherapy.DNA hypo-methylating agents and sickle cell disease.Inhibition of G9a methyltransferase stimulates fetal hemoglobin production by facilitating LCR/γ-globin looping.Developmental- and differentiation-specific patterns of human gamma- and beta-globin promoter DNA methylation.Epigenetic regulation of prostate cancerThe silence of the genes: epigenetic disturbances in haematopoietic malignancies.Spatial and temporal dynamics of the endothelium.An open-label, single-arm, phase I/II study of lower-dose decitabine based therapy in patients with advanced hepatocellular carcinomaA high-throughput screen of inactive X chromosome reactivation identifies the enhancement of DNA demethylation by 5-aza-2'-dC upon inhibition of ribonucleotide reductase.Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo.Endothelial biomedicine: its status as an interdisciplinary field, its progress as a basic science, and its translational bench-to-bedside gap.Hydroxyurea with AKT2 inhibition decreases vaso-occlusive events in sickle cell disease miceDecitabine for Treatment of Myelodysplastic Syndromes in Chinese Patients: An Open-Label, Phase-3b StudyInvestigational agents for sickle cell disease.
P2860
Q26742061-FC2778A8-F784-43ED-B578-A49CAC7B1EB0Q26822810-14B54889-B0DD-4466-8904-3EDD8EA1BEA6Q27000542-47B83736-2283-4AD9-A39F-6A798E3E9E7CQ27303155-8BBB490E-A9A9-4EFE-A52C-03DA1D20D371Q27693287-258C92E5-4BA4-4C8E-9BBD-3C2BA7AB07CDQ28384242-F929F515-FF3E-41C7-816B-C5B1E9795577Q28475636-49134FE0-FA34-434B-AB2F-AE43E7C6AEB2Q28551832-CFF99565-504A-418C-AB2A-4ACA339F475BQ28741003-ED1CD566-9C4A-4CE7-81B6-6DDE3152F0E9Q30601237-4FC4A732-C2A6-455B-B212-CCA4B46092EBQ33416734-11940846-3157-4C5A-A27A-220A2CB8E6B5Q33628389-22D07431-3ED3-4CF1-90BB-E27D8FBE98CAQ33651543-AF4B69D2-E357-422F-B978-A1C6694935A4Q33789556-7331AD9C-45E3-4463-B6EB-C73B33AF1AA0Q33999887-39AD9443-789D-43AB-B69C-114F61C674C3Q34013796-8A97A8BF-25CC-4244-8756-4F42CB9F8FCAQ34187526-AA0B0494-9E19-443C-82E8-E72E2A8D1ECFQ34731480-4A73C605-0FFB-451D-B119-323A4666842DQ34768789-87B9F1F8-87C8-46D7-A8E7-F23049ED22C1Q35114500-7345C639-5281-4B84-8AE6-EF442D8D9004Q35183982-D3C4F891-2C09-489A-9343-06CC2EBB731BQ35212344-433C0FD7-91C7-4D16-B71E-16D41102DC72Q35220342-724FFBAD-0BD1-4F7E-9CB0-0BF67476AC36Q35683885-F0E5DB2E-112B-44AC-BE47-75B85B5510F5Q35723452-E5F2D164-189C-4356-926D-A0FA5D4A0FFCQ35750354-6091B03B-1204-485A-9518-1A3180B8D51FQ35843658-9990C4A1-080B-4319-855B-F154068F96C0Q35870510-DFE41EAA-478A-4E91-8243-854D3312AFCCQ35904956-F3F61AB8-9C8F-4DA8-B1C9-76A1E1B308B9Q35925062-C335CD69-6E31-4536-9779-8AEBDE83D881Q36001910-8B2D76CF-5BE7-4738-8923-2C131E974650Q36066276-ED3E909A-EE6A-456F-8129-E6213E51CFF6Q36126944-4A78254C-01AA-44BD-B55C-1D5DAF479842Q36140936-70E19644-3635-4D8C-BA4C-1976DC9C8F31Q36159688-BD674181-F756-4A3E-A6B8-460F8B27F858Q36266756-52D16670-1E8B-44DB-A498-4B5D60C43C1EQ36314380-BBC97563-5867-481E-9106-869242509798Q36322782-C43944AE-7AF8-48D9-8DF5-A01F63E9FD0AQ36327153-F207B60B-840E-46FF-BF67-5B3E2F9B5327Q36543049-83036D40-3243-4415-83FC-D0256B84585E
P2860
Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Effects of 5-aza-2'-deoxycytid ...... ents with sickle cell disease.
@en
Effects of 5-aza-2'-deoxycytid ...... ents with sickle cell disease.
@nl
type
label
Effects of 5-aza-2'-deoxycytid ...... ents with sickle cell disease.
@en
Effects of 5-aza-2'-deoxycytid ...... ents with sickle cell disease.
@nl
prefLabel
Effects of 5-aza-2'-deoxycytid ...... ents with sickle cell disease.
@en
Effects of 5-aza-2'-deoxycytid ...... ents with sickle cell disease.
@nl
P2093
P1433
P1476
Effects of 5-aza-2'-deoxycytid ...... ents with sickle cell disease.
@en
P2093
Cheryl A Hillery
Don Lavelle
Joseph DeSimone
Linda Bressler
Louise Dorn
Robert Molokie
Ronald Hoffman
Stefana Gavazova
Yi-Hsiang Chen
Yogen Saunthararajah
P304
P356
10.1182/BLOOD-2003-05-1738
P407
P577
2003-08-07T00:00:00Z